IPR decision: Apr. 20, 2020
|
AIA Review #
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent
|
Respondent
|
Status
|
|
IPR2019-01446
|
08/01/2019
|
01/31/2020
|
Nevakar, Inc.
|
9,913,853
|
Cipla
|
Terminated-Dismissed
|
US 9,913,853 (Cipla Ltd.; Exp: 11/3/2036)
1. A liquid composition comprising fosaprepitant or a salt thereof and at least one liquid excipient, wherein after storage at 2-8.degree. C. for at least 1 month, aprepitant is present in an amount concentration of no more than 10%, wherein the composition is ready-to-use or ready-to-dilute.
17. A liquid pharmaceutical composition comprising: a) fosaprepitant dimeglumine in an amount from 50-250 mg; b) at least one salt of ethylenediaminetetraacetic acid in an amount from 10-100 mg; c) albumin in an amount from 250 mg-100 g; and d) water in an amount from 3-300 ml.
20. A liquid pharmaceutical composition comprising: a) fosaprepitant dimeglumine in an amount from 50-250 mg; and b) at least one solubilizer in an amount from 1-5 ml.
Leave a Reply